Skip to main content
  • Regulatory Update

Malaysia MDA Announces Agreement with China NMPA

This agreement paves the way for facilitating medical device market access for manufacturers between Malaysia and China.

People shaking hands at a business event

January 16, 2025

By Yu Seen Ng, Janet Zhang, and Evangeline Loh

Medical device regulators in Malaysia and China have established an agreement to support more streamlined market access between the two markets for medical device manufacturers.

Background

Malaysian Medical Device Authority (MDA) Chief Executive Dr. Muralitharan Paramasua hosted the 2025 keynote address (January 14).

Many programs were presented: e-labeling, UDI, import permit, guidance documents, Medcast 3.0, additional recognized ASEAN countries, and Class A fees. This update focuses on one of the global harmonization/regulatory reliance initiatives.

Joint agreement between China and Malaysia signed

Dr. Paramasua announced that China and Malaysia had signed an agreement (January 13) to facilitate medical device reviews between China's National Products Administration (NMPA) and Medical Device Authority (MDA), respectively.

While the evaluation framework is in development, the proposed assessment would allow Class C and Class D products authorized by NMPA to be registered in Malaysia in one to two months. Similarly, Class B products authorized by MDA would be registered in China in one to two months.

Reducing review timeframes for medical market access

It was explained that most of the products registered with NMPA brought into Malaysia from China are Class C and Class D. And most of the products manufactured in Malaysia are Class B (and Class A). Dr. Paramasua mentioned that a Class B product permitted by MDA could require as long as two years before a complete review by NMPA for access to the China market. Hence, the program is proposed to reduce the review times.

Concluding remarks

Emergo will continue to monitor developments related to this Joint Assessment. However, our experience is consistent with this as well. In addition, the MDA announced that there are current discussions with the South Korean Ministry for Food and Drug Safety (MDFS).

The prospects for 2025 and regulatory reliance are exciting, and these initiatives from the MDA certainly add to that.

 

 

 

X

Request more information from our specialists

Thanks for your interest in our products and services. Let's collect some information so we can connect you with the right person.

Please wait…